RU2015103891A - Комплексы белков цитомегаловируса - Google Patents
Комплексы белков цитомегаловируса Download PDFInfo
- Publication number
- RU2015103891A RU2015103891A RU2015103891A RU2015103891A RU2015103891A RU 2015103891 A RU2015103891 A RU 2015103891A RU 2015103891 A RU2015103891 A RU 2015103891A RU 2015103891 A RU2015103891 A RU 2015103891A RU 2015103891 A RU2015103891 A RU 2015103891A
- Authority
- RU
- Russia
- Prior art keywords
- hcmv
- complex
- glycoprotein
- nucleic acid
- membrane proteins
- Prior art date
Links
- 241000701022 Cytomegalovirus Species 0.000 title 1
- 102000007474 Multiprotein Complexes Human genes 0.000 title 1
- 108010085220 Multiprotein Complexes Proteins 0.000 title 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims abstract 49
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract 28
- 102000039446 nucleic acids Human genes 0.000 claims abstract 23
- 108020004707 nucleic acids Proteins 0.000 claims abstract 23
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 23
- 102000003886 Glycoproteins Human genes 0.000 claims abstract 20
- 108090000288 Glycoproteins Proteins 0.000 claims abstract 20
- 238000000034 method Methods 0.000 claims abstract 20
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract 6
- 239000012634 fragment Substances 0.000 claims abstract 3
- 230000013595 glycosylation Effects 0.000 claims abstract 3
- 238000006206 glycosylation reaction Methods 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 210000004962 mammalian cell Anatomy 0.000 claims abstract 2
- 238000000746 purification Methods 0.000 claims abstract 2
- 238000003259 recombinant expression Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 9
- 241000710929 Alphavirus Species 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 5
- 235000018102 proteins Nutrition 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 3
- 230000003053 immunization Effects 0.000 claims 3
- 238000002649 immunization Methods 0.000 claims 3
- 230000037452 priming Effects 0.000 claims 3
- 102100028253 Breast cancer anti-estrogen resistance protein 3 Human genes 0.000 claims 2
- 241000710188 Encephalomyocarditis virus Species 0.000 claims 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 2
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 claims 2
- 101710144127 Non-structural protein 1 Proteins 0.000 claims 2
- 101710144128 Non-structural protein 2 Proteins 0.000 claims 2
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 2
- 102100031776 SH2 domain-containing protein 3A Human genes 0.000 claims 2
- 102100021798 SH2 domain-containing protein 3C Human genes 0.000 claims 2
- 102100031056 Serine protease 57 Human genes 0.000 claims 2
- 101710197596 Serine protease 57 Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 235000004252 protein component Nutrition 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668975P | 2012-07-06 | 2012-07-06 | |
| US61/668,975 | 2012-07-06 | ||
| US201361770257P | 2013-02-27 | 2013-02-27 | |
| US61/770,257 | 2013-02-27 | ||
| PCT/EP2013/063750 WO2014005959A1 (en) | 2012-07-06 | 2013-06-29 | Complexes of cytomegalovirus proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015103891A true RU2015103891A (ru) | 2016-08-27 |
Family
ID=48783208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015103891A RU2015103891A (ru) | 2012-07-06 | 2013-06-29 | Комплексы белков цитомегаловируса |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9683022B2 (enExample) |
| EP (1) | EP2869843B1 (enExample) |
| JP (3) | JP2015522581A (enExample) |
| KR (1) | KR20150031322A (enExample) |
| CN (1) | CN104853771A (enExample) |
| AU (1) | AU2013286093B2 (enExample) |
| CA (1) | CA2878344A1 (enExample) |
| ES (1) | ES2753138T3 (enExample) |
| GB (1) | GB2513768B (enExample) |
| HK (1) | HK1210037A1 (enExample) |
| IL (1) | IL236261A0 (enExample) |
| IN (1) | IN2014KN02929A (enExample) |
| MX (2) | MX378747B (enExample) |
| RU (1) | RU2015103891A (enExample) |
| SG (1) | SG11201408328VA (enExample) |
| WO (1) | WO2014005959A1 (enExample) |
| ZA (1) | ZA201409364B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX378747B (es) | 2012-07-06 | 2025-03-10 | Glaxosmithkline Biologicals S A Star | Complejos de proteínas de citomegalovirus. |
| AU2013293570B2 (en) | 2012-07-27 | 2019-05-23 | City Of Hope | An MVA vaccine for delivery of a UL128 complex and preventing CMV infection |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| HRP20211015T1 (hr) * | 2013-12-03 | 2021-10-01 | Hookipa Biotech Gmbh | Cjepivo protiv citomegalovirusa (cmv) |
| US20170119874A1 (en) * | 2014-04-23 | 2017-05-04 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| EP3139953A1 (en) * | 2014-05-08 | 2017-03-15 | Pfizer Inc. | Means and methods for treating cmv |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| EP3047856A1 (en) * | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
| WO2017044895A2 (en) | 2015-09-10 | 2017-03-16 | City Of Hope | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF |
| MA46316A (fr) * | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| AU2017207744A1 (en) | 2016-01-11 | 2018-07-26 | Verndari, Inc. | Microneedle compositions and methods of using same |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP2020515522A (ja) * | 2017-01-27 | 2020-05-28 | ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | 免疫応答を誘導するヘルペスウイルスエンベロープタンパク質の組み合わせのワクチン組成物 |
| LT3606942T (lt) | 2017-04-04 | 2025-10-10 | Savaiminės sąrankos baltymų nanostruktūros, eksponuojančios paramiksoviruso ir (arba) pneumoviruso f baltymus ir jų naudojimas | |
| CA3060019A1 (en) | 2017-04-19 | 2018-10-25 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| WO2019020480A1 (en) * | 2017-07-24 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES |
| BR112020001052A2 (pt) | 2017-07-28 | 2020-09-08 | Janssen Vaccines & Prevention B.V. | métodos e composições para imunizações heterólogas com reprna |
| BR112020004747A2 (pt) * | 2017-09-13 | 2020-09-24 | Sanofi Pasteur | composição imunogênica de citomegalovírus humano |
| AU2019228551B2 (en) * | 2018-02-28 | 2025-07-24 | University Of Washington | Self-assembling nanostructure vaccines |
| CN112638411B (zh) | 2018-05-04 | 2025-03-04 | 斯拜生物技术有限公司 | 疫苗组合物 |
| CA3116175A1 (en) | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| JP7179872B2 (ja) | 2018-12-10 | 2022-11-29 | Ｋｍバイオロジクス株式会社 | サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン |
| US11629172B2 (en) * | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP4004018A1 (en) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
| KR102837045B1 (ko) * | 2020-06-09 | 2025-07-23 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신 |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4237085A1 (en) | 2020-10-28 | 2023-09-06 | Sanofi Pasteur | Liposomes containing tlr4 agonist, preparation and uses thereof |
| MX2023009891A (es) * | 2021-02-24 | 2023-11-22 | Pfizer | Nuevas regiones susceptibles a modificarse por fármacos en el polipéptido de glucoproteína b del citomegalovirus humano y métodos de uso de las mismas. |
| WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0452364B1 (en) | 1988-12-22 | 2002-05-22 | Genentech, Inc. | Method for preparing water soluble polypeptides |
| KR920701453A (ko) | 1989-03-17 | 1992-08-11 | 미리엄 디. 멕코나헤이 | 유전자발현의 외부조절 |
| CA2088599A1 (en) | 1990-08-02 | 1992-02-03 | Carol A. Pachl | Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system |
| US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US5815900A (en) | 1995-03-06 | 1998-10-06 | Matsushita Electric Industrial Co., Ltd. | Method of manufacturing a surface acoustic wave module |
| WO2004076645A2 (en) * | 2003-02-27 | 2004-09-10 | University Of Massachusetts | Compositions and methods for cytomegalovirus treatment |
| CA2654563A1 (en) | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| US7947274B2 (en) * | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| WO2011106607A2 (en) * | 2010-02-26 | 2011-09-01 | Juvaris Biotherapeutics, Inc. | Subunit vaccines for herpes viruses and methods of use |
| ES2649896T3 (es) | 2010-07-06 | 2018-01-16 | Glaxosmithkline Biologicals Sa | Emulsiones catiónicas de aceite en agua |
| BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
| WO2012015211A2 (ko) | 2010-07-30 | 2012-02-02 | 주식회사종근당 | 사이클로스포린 에이 함유 점안제 조성물 |
| WO2012034025A2 (en) | 2010-09-09 | 2012-03-15 | Virginia Commonwealth University | Human cytomegalovirus vaccine |
| CA2814386C (en) | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| WO2012106377A2 (en) | 2011-01-31 | 2012-08-09 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| EP2729168A2 (en) | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| SG10201602456WA (en) * | 2011-08-31 | 2016-04-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| MX378747B (es) | 2012-07-06 | 2025-03-10 | Glaxosmithkline Biologicals S A Star | Complejos de proteínas de citomegalovirus. |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
-
2013
- 2013-06-29 MX MX2018000675A patent/MX378747B/es unknown
- 2013-06-29 KR KR1020157002267A patent/KR20150031322A/ko not_active Withdrawn
- 2013-06-29 CN CN201380036145.0A patent/CN104853771A/zh active Pending
- 2013-06-29 RU RU2015103891A patent/RU2015103891A/ru not_active Application Discontinuation
- 2013-06-29 EP EP13736518.5A patent/EP2869843B1/en active Active
- 2013-06-29 AU AU2013286093A patent/AU2013286093B2/en not_active Ceased
- 2013-06-29 IN IN2929KON2014 patent/IN2014KN02929A/en unknown
- 2013-06-29 ES ES13736518T patent/ES2753138T3/es active Active
- 2013-06-29 JP JP2015519155A patent/JP2015522581A/ja active Pending
- 2013-06-29 US US14/410,461 patent/US9683022B2/en active Active
- 2013-06-29 WO PCT/EP2013/063750 patent/WO2014005959A1/en not_active Ceased
- 2013-06-29 MX MX2014015496A patent/MX355469B/es active IP Right Grant
- 2013-06-29 SG SG11201408328VA patent/SG11201408328VA/en unknown
- 2013-06-29 CA CA2878344A patent/CA2878344A1/en not_active Abandoned
- 2013-06-29 GB GB1413863.0A patent/GB2513768B/en active Active
- 2013-06-29 HK HK15110880.5A patent/HK1210037A1/xx unknown
-
2014
- 2014-12-15 IL IL236261A patent/IL236261A0/en unknown
- 2014-12-18 ZA ZA2014/09364A patent/ZA201409364B/en unknown
-
2017
- 2017-05-16 US US15/596,066 patent/US10287322B2/en active Active
- 2017-08-01 JP JP2017149178A patent/JP2017192399A/ja active Pending
- 2017-08-01 JP JP2017149179A patent/JP2017192400A/ja active Pending
-
2019
- 2019-03-25 US US16/363,127 patent/US20190211064A1/en not_active Abandoned
-
2021
- 2021-12-15 US US17/551,867 patent/US20220106364A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX355469B (es) | 2018-04-19 |
| WO2014005959A1 (en) | 2014-01-09 |
| US10287322B2 (en) | 2019-05-14 |
| MX2014015496A (es) | 2015-03-06 |
| CN104853771A (zh) | 2015-08-19 |
| US20160159864A1 (en) | 2016-06-09 |
| US20170320916A1 (en) | 2017-11-09 |
| JP2017192399A (ja) | 2017-10-26 |
| AU2013286093B2 (en) | 2018-01-04 |
| SG11201408328VA (en) | 2015-02-27 |
| JP2017192400A (ja) | 2017-10-26 |
| US20220106364A1 (en) | 2022-04-07 |
| IN2014KN02929A (enExample) | 2015-05-08 |
| HK1210037A1 (en) | 2016-04-15 |
| IL236261A0 (en) | 2015-02-26 |
| EP2869843B1 (en) | 2019-08-07 |
| US20190211064A1 (en) | 2019-07-11 |
| ES2753138T3 (es) | 2020-04-07 |
| JP2015522581A (ja) | 2015-08-06 |
| MX378747B (es) | 2025-03-10 |
| US9683022B2 (en) | 2017-06-20 |
| GB2513768A (en) | 2014-11-05 |
| CA2878344A1 (en) | 2014-01-09 |
| KR20150031322A (ko) | 2015-03-23 |
| EP2869843A1 (en) | 2015-05-13 |
| GB2513768B (en) | 2015-04-15 |
| ZA201409364B (en) | 2017-08-30 |
| GB201413863D0 (en) | 2014-09-17 |
| AU2013286093A1 (en) | 2015-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015103891A (ru) | Комплексы белков цитомегаловируса | |
| JP2015522581A5 (enExample) | ||
| JP7613685B2 (ja) | 新規ｒｓｖ ｒｎａ分子及びワクチン接種用組成物 | |
| AU699384B2 (en) | Alphavirus cDNA vectors | |
| US6224879B1 (en) | Alphavirus expression vector | |
| JP2019530466A5 (enExample) | ||
| EP0561890B1 (en) | Dna expression systems based on alphaviruses | |
| WO2019193183A2 (en) | Novel yellow fever nucleic acid molecules for vaccination | |
| WO2008119827A1 (en) | Transreplicase constructs | |
| RU2018131966A (ru) | Рнк-репликон для универсальной и эффективной генной экспрессии | |
| JP2023520354A (ja) | コロナウイルスワクチン | |
| WO2022166959A1 (zh) | 顺式复制子构建体 | |
| AU2008338803A1 (en) | Methods of generating alphavirus particles | |
| RU2012140691A (ru) | Вакцины на основе неинтегрирующегося ретровирусного вектора | |
| CN118109489A (zh) | 编码新型冠状病毒的结构蛋白的核酸分子及其疫苗的应用 | |
| CN118086288B (zh) | 多顺反子的自放大rna及制备方法 | |
| ES2585735T3 (es) | Nuevas proteínas de fusión y su aplicación para la preparación de vacunas contra la hepatitis C | |
| CN111040998B (zh) | 一种稳定表达狂犬病毒糖蛋白细胞株的构建及其应用 | |
| ES2544702T3 (es) | Vacunas en forma de ADNi y métodos para utilizarlas | |
| PH12018502197A1 (en) | Improved method for producing virus like particles | |
| WO2010019437A1 (en) | Alphavirus packaging cell lines | |
| RU2014129220A (ru) | Новый аттенуированный полиовирус: pv-1 mono-cre-x | |
| Karlsson et al. | Live viral vectors: Semliki Forest virus | |
| CN120888569A (zh) | 一种自复制mRNA疫苗及其制备方法和用途 | |
| RU2013139565A (ru) | Усовершенствованная праймерная и бустерная вакцина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20190503 |